IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Upregulation of BRCA1, ERBB2 and TP53 marker genes expression in breast cancer patients.

Author: ABDULRAZZAQ ZGHAIR, ROHIT SHARMA, MOHAMMED ALFAHAM, ANIL K SHARMA*
Abstract: Breast cancer is considered as the most common malignant disease, especially among Indian women that accounts for the highest rate of morbidity and mortality. BRCA-1, ERBB-2 and TP-53 are amongst the high risk genes of breast cancer. Mutations in these genes account for a considerably higher incidence of breast cancer initiation and development. In breast cancer , BRCA-1 gene is considered as the most predisposing genetic factor. Similarly, ERBB-2 and TP-53 are also observed as the main prognostic markers in the treatment of breast cancer. This study was designed to know the gene expression profile of the molecular markers namely, breast cancer 1 (BRCA-1), human epidermal growth factor receptor 2 (ERBB-2) and tumor suppressor gene (TP-53) expression by the real time polymerase chain reaction (PCR). The mutational analysis in particular exons of BRCA-1 (exon 11),ERBB-2 (exon 16) and TP-53 (exon 5) was further investigated by Sanger-Sequencing in the above breast cancer patients of north Indian origin. The TP-53 mRNA levels have been significantly expressed in cancer tissues as compared to the normal ones. Similar trends were observed with BRCA-1 and ERBB-2 mRNA expression as well. We conclude from this work that the differential gene expressions of BRCA-1, ERBB-2 and TP-53 at the mRNA level may act as a diagnostic marker with a significant prognostic value in Breast cancer patients.
Keyword: Breast cancer , BRCA-1, ERBB-2 , TP-53, gene expression, prognosis
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus